Tolerable and curable treatment in HIV/HCV co-infected patients using anti-HCV direct antiviral agents: a real-world observation in China
Objective No brand direct-acting antiviral agents (DAAs) are available for treatment of HIV-1/HCV co-infected patients in China. This study aimed to observe the therapeutic efficacy and safety of generic DAAs for affected Chinese patients. Design Real-world setting to elucidate whether DAAs were tol...
Gespeichert in:
| Veröffentlicht in: | Hepatology international 2018-09, Vol.12 (5), p.465-473 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 473 |
|---|---|
| container_issue | 5 |
| container_start_page | 465 |
| container_title | Hepatology international |
| container_volume | 12 |
| creator | Li, Yuanyuan Li, Linghua Liu, Jun Zhang, Da-Wei Zhao, Fang Wang, Li Mahemure, Aizezi Xie, Ronghui Lei, Suyun Cai, Weiping Wang, Xicheng Shu, Zhanjun Chen, Xiejie Wang, Hui Wang, Fu-Sheng |
| description | Objective
No brand direct-acting antiviral agents (DAAs) are available for treatment of HIV-1/HCV co-infected patients in China. This study aimed to observe the therapeutic efficacy and safety of generic DAAs for affected Chinese patients.
Design
Real-world setting to elucidate whether DAAs were tolerated and effective in HIV-1/HCV co-infected patients.
Methods
176 HIV-1/HCV co-infected patients received anti-HCV DAA treatment together with ART regimens for HIV infection. Among the 176 patients, 99 patients were treated with SOF + DCV ± RBV, 60 patients were treated with SOF + LDV ± RBV, and 17 patients received SOF + RBV ± Peg-IFN regimens, for 12 or 24 weeks, respectively. The primary endpoint was undetectable HCV RNA 12 weeks after therapy was completed (SVR12). Data pertaining to safety and adverse events were analyzed.
Results
151/176 HIV-1/HCV co-infected patients finished the treatment and 12-week follow-up. SVR12 for the patients treated with regimens of SOF + DCV, SOF + DCV+RBV, SOF + Peg-IFN+RBV, SOF + RBV, SOF + LDV, and SOF + LDV+RBV for 12 or 24 weeks was 100% (75/75), 100% (11/11), 100% (14/14), 100% (2/2), 95.2% (40/42), and 100% (7/7), respectively. HIV-1/HCV co-infected patients with liver cirrhosis achieved well SRV12. Notably, there was no significant difference in adverse effects among patients with different baseline CD4
+
T-cell count in those who received DAA regimens with or without Peg-IFN and RBV.
Conclusion
We showed generic SOF + DCV and SOF + LDV regimens were well tolerated and with high efficiency. Patient’s baseline CD4
+
T-cell count did not exhibit significant difference in adverse effects. |
| doi_str_mv | 10.1007/s12072-018-9891-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2102320919</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2101675739</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-67412f2fb9d155e61add1668cf60ceb44cd31941cdb4385700a4817b4e5989e03</originalsourceid><addsrcrecordid>eNp9kc9u1DAQxiMEomXhAbggS1y4mM74XxJuaEXZSpW4lF4tx3YWV1lnsZNWPAJvXYeUIiHByWPN7_tmNF9VvUZ4jwD1WUYGNaOADW2bFmn7pDrFlisKUuDTx5rzk-pFzjcAUipUz6sTDgw4b_C0-nk1Dj6ZbvDEREfsvNZT8mY6-DiREMnu4vpst70mdqQh9t5O3pGjmUJpZzLnEPdFOwW6MC6kAvz634ZkBmL2C_aBGFIsB3o3psGRscs-3RaLMS4Dtt9CNC-rZ70Zsn_18G6qr-efrrY7evnl88X24yW1AmCiqhbIetZ3rUMpvULjHCrV2F6B9Z0Q1nFsBVrXCd7IGsCIButOeFlu5IFvqner7zGN32efJ30I2fphMNGPc9YMgXEGbTnepnr7F3ozzimW7TRTrZQgGs7-SyGgqmXNFy9cKZvGnJPv9TGFg0k_NIJe0tRrmrqkqZc09aJ58-A8dwfvHhW_4ysAW4FcWnHv05_R_3a9B6S5qNQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2101675739</pqid></control><display><type>article</type><title>Tolerable and curable treatment in HIV/HCV co-infected patients using anti-HCV direct antiviral agents: a real-world observation in China</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Li, Yuanyuan ; Li, Linghua ; Liu, Jun ; Zhang, Da-Wei ; Zhao, Fang ; Wang, Li ; Mahemure, Aizezi ; Xie, Ronghui ; Lei, Suyun ; Cai, Weiping ; Wang, Xicheng ; Shu, Zhanjun ; Chen, Xiejie ; Wang, Hui ; Wang, Fu-Sheng</creator><creatorcontrib>Li, Yuanyuan ; Li, Linghua ; Liu, Jun ; Zhang, Da-Wei ; Zhao, Fang ; Wang, Li ; Mahemure, Aizezi ; Xie, Ronghui ; Lei, Suyun ; Cai, Weiping ; Wang, Xicheng ; Shu, Zhanjun ; Chen, Xiejie ; Wang, Hui ; Wang, Fu-Sheng</creatorcontrib><description>Objective
No brand direct-acting antiviral agents (DAAs) are available for treatment of HIV-1/HCV co-infected patients in China. This study aimed to observe the therapeutic efficacy and safety of generic DAAs for affected Chinese patients.
Design
Real-world setting to elucidate whether DAAs were tolerated and effective in HIV-1/HCV co-infected patients.
Methods
176 HIV-1/HCV co-infected patients received anti-HCV DAA treatment together with ART regimens for HIV infection. Among the 176 patients, 99 patients were treated with SOF + DCV ± RBV, 60 patients were treated with SOF + LDV ± RBV, and 17 patients received SOF + RBV ± Peg-IFN regimens, for 12 or 24 weeks, respectively. The primary endpoint was undetectable HCV RNA 12 weeks after therapy was completed (SVR12). Data pertaining to safety and adverse events were analyzed.
Results
151/176 HIV-1/HCV co-infected patients finished the treatment and 12-week follow-up. SVR12 for the patients treated with regimens of SOF + DCV, SOF + DCV+RBV, SOF + Peg-IFN+RBV, SOF + RBV, SOF + LDV, and SOF + LDV+RBV for 12 or 24 weeks was 100% (75/75), 100% (11/11), 100% (14/14), 100% (2/2), 95.2% (40/42), and 100% (7/7), respectively. HIV-1/HCV co-infected patients with liver cirrhosis achieved well SRV12. Notably, there was no significant difference in adverse effects among patients with different baseline CD4
+
T-cell count in those who received DAA regimens with or without Peg-IFN and RBV.
Conclusion
We showed generic SOF + DCV and SOF + LDV regimens were well tolerated and with high efficiency. Patient’s baseline CD4
+
T-cell count did not exhibit significant difference in adverse effects.</description><identifier>ISSN: 1936-0533</identifier><identifier>EISSN: 1936-0541</identifier><identifier>DOI: 10.1007/s12072-018-9891-9</identifier><identifier>PMID: 30203381</identifier><language>eng</language><publisher>New Delhi: Springer India</publisher><subject>Adult ; Antiretroviral therapy ; Antiviral agents ; Antiviral Agents - therapeutic use ; Antiviral drugs ; CD4 antigen ; China ; Cirrhosis ; Coinfection - drug therapy ; Colorectal Surgery ; Drug Therapy, Combination ; Drugs, Generic - therapeutic use ; Female ; Follow-Up Studies ; Hepatitis C, Chronic - drug therapy ; Hepatology ; HIV ; HIV Infections - drug therapy ; HIV-1 ; Human immunodeficiency virus ; Humans ; Interferon ; Liver ; Liver cirrhosis ; Lymphocytes T ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Original Article ; Patients ; Retrospective Studies ; Ribonucleic acid ; RNA ; Safety ; Side effects ; Surgery ; Treatment Outcome</subject><ispartof>Hepatology international, 2018-09, Vol.12 (5), p.465-473</ispartof><rights>Asian Pacific Association for the Study of the Liver 2018</rights><rights>Hepatology International is a copyright of Springer, (2018). All Rights Reserved.</rights><rights>Asian Pacific Association for the Study of the Liver 2018.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-67412f2fb9d155e61add1668cf60ceb44cd31941cdb4385700a4817b4e5989e03</citedby><cites>FETCH-LOGICAL-c400t-67412f2fb9d155e61add1668cf60ceb44cd31941cdb4385700a4817b4e5989e03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12072-018-9891-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12072-018-9891-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30203381$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Yuanyuan</creatorcontrib><creatorcontrib>Li, Linghua</creatorcontrib><creatorcontrib>Liu, Jun</creatorcontrib><creatorcontrib>Zhang, Da-Wei</creatorcontrib><creatorcontrib>Zhao, Fang</creatorcontrib><creatorcontrib>Wang, Li</creatorcontrib><creatorcontrib>Mahemure, Aizezi</creatorcontrib><creatorcontrib>Xie, Ronghui</creatorcontrib><creatorcontrib>Lei, Suyun</creatorcontrib><creatorcontrib>Cai, Weiping</creatorcontrib><creatorcontrib>Wang, Xicheng</creatorcontrib><creatorcontrib>Shu, Zhanjun</creatorcontrib><creatorcontrib>Chen, Xiejie</creatorcontrib><creatorcontrib>Wang, Hui</creatorcontrib><creatorcontrib>Wang, Fu-Sheng</creatorcontrib><title>Tolerable and curable treatment in HIV/HCV co-infected patients using anti-HCV direct antiviral agents: a real-world observation in China</title><title>Hepatology international</title><addtitle>Hepatol Int</addtitle><addtitle>Hepatol Int</addtitle><description>Objective
No brand direct-acting antiviral agents (DAAs) are available for treatment of HIV-1/HCV co-infected patients in China. This study aimed to observe the therapeutic efficacy and safety of generic DAAs for affected Chinese patients.
Design
Real-world setting to elucidate whether DAAs were tolerated and effective in HIV-1/HCV co-infected patients.
Methods
176 HIV-1/HCV co-infected patients received anti-HCV DAA treatment together with ART regimens for HIV infection. Among the 176 patients, 99 patients were treated with SOF + DCV ± RBV, 60 patients were treated with SOF + LDV ± RBV, and 17 patients received SOF + RBV ± Peg-IFN regimens, for 12 or 24 weeks, respectively. The primary endpoint was undetectable HCV RNA 12 weeks after therapy was completed (SVR12). Data pertaining to safety and adverse events were analyzed.
Results
151/176 HIV-1/HCV co-infected patients finished the treatment and 12-week follow-up. SVR12 for the patients treated with regimens of SOF + DCV, SOF + DCV+RBV, SOF + Peg-IFN+RBV, SOF + RBV, SOF + LDV, and SOF + LDV+RBV for 12 or 24 weeks was 100% (75/75), 100% (11/11), 100% (14/14), 100% (2/2), 95.2% (40/42), and 100% (7/7), respectively. HIV-1/HCV co-infected patients with liver cirrhosis achieved well SRV12. Notably, there was no significant difference in adverse effects among patients with different baseline CD4
+
T-cell count in those who received DAA regimens with or without Peg-IFN and RBV.
Conclusion
We showed generic SOF + DCV and SOF + LDV regimens were well tolerated and with high efficiency. Patient’s baseline CD4
+
T-cell count did not exhibit significant difference in adverse effects.</description><subject>Adult</subject><subject>Antiretroviral therapy</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Antiviral drugs</subject><subject>CD4 antigen</subject><subject>China</subject><subject>Cirrhosis</subject><subject>Coinfection - drug therapy</subject><subject>Colorectal Surgery</subject><subject>Drug Therapy, Combination</subject><subject>Drugs, Generic - therapeutic use</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatology</subject><subject>HIV</subject><subject>HIV Infections - drug therapy</subject><subject>HIV-1</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Interferon</subject><subject>Liver</subject><subject>Liver cirrhosis</subject><subject>Lymphocytes T</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Original Article</subject><subject>Patients</subject><subject>Retrospective Studies</subject><subject>Ribonucleic acid</subject><subject>RNA</subject><subject>Safety</subject><subject>Side effects</subject><subject>Surgery</subject><subject>Treatment Outcome</subject><issn>1936-0533</issn><issn>1936-0541</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kc9u1DAQxiMEomXhAbggS1y4mM74XxJuaEXZSpW4lF4tx3YWV1lnsZNWPAJvXYeUIiHByWPN7_tmNF9VvUZ4jwD1WUYGNaOADW2bFmn7pDrFlisKUuDTx5rzk-pFzjcAUipUz6sTDgw4b_C0-nk1Dj6ZbvDEREfsvNZT8mY6-DiREMnu4vpst70mdqQh9t5O3pGjmUJpZzLnEPdFOwW6MC6kAvz634ZkBmL2C_aBGFIsB3o3psGRscs-3RaLMS4Dtt9CNC-rZ70Zsn_18G6qr-efrrY7evnl88X24yW1AmCiqhbIetZ3rUMpvULjHCrV2F6B9Z0Q1nFsBVrXCd7IGsCIButOeFlu5IFvqner7zGN32efJ30I2fphMNGPc9YMgXEGbTnepnr7F3ozzimW7TRTrZQgGs7-SyGgqmXNFy9cKZvGnJPv9TGFg0k_NIJe0tRrmrqkqZc09aJ58-A8dwfvHhW_4ysAW4FcWnHv05_R_3a9B6S5qNQ</recordid><startdate>20180901</startdate><enddate>20180901</enddate><creator>Li, Yuanyuan</creator><creator>Li, Linghua</creator><creator>Liu, Jun</creator><creator>Zhang, Da-Wei</creator><creator>Zhao, Fang</creator><creator>Wang, Li</creator><creator>Mahemure, Aizezi</creator><creator>Xie, Ronghui</creator><creator>Lei, Suyun</creator><creator>Cai, Weiping</creator><creator>Wang, Xicheng</creator><creator>Shu, Zhanjun</creator><creator>Chen, Xiejie</creator><creator>Wang, Hui</creator><creator>Wang, Fu-Sheng</creator><general>Springer India</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20180901</creationdate><title>Tolerable and curable treatment in HIV/HCV co-infected patients using anti-HCV direct antiviral agents: a real-world observation in China</title><author>Li, Yuanyuan ; Li, Linghua ; Liu, Jun ; Zhang, Da-Wei ; Zhao, Fang ; Wang, Li ; Mahemure, Aizezi ; Xie, Ronghui ; Lei, Suyun ; Cai, Weiping ; Wang, Xicheng ; Shu, Zhanjun ; Chen, Xiejie ; Wang, Hui ; Wang, Fu-Sheng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-67412f2fb9d155e61add1668cf60ceb44cd31941cdb4385700a4817b4e5989e03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Antiretroviral therapy</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Antiviral drugs</topic><topic>CD4 antigen</topic><topic>China</topic><topic>Cirrhosis</topic><topic>Coinfection - drug therapy</topic><topic>Colorectal Surgery</topic><topic>Drug Therapy, Combination</topic><topic>Drugs, Generic - therapeutic use</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatology</topic><topic>HIV</topic><topic>HIV Infections - drug therapy</topic><topic>HIV-1</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Interferon</topic><topic>Liver</topic><topic>Liver cirrhosis</topic><topic>Lymphocytes T</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Original Article</topic><topic>Patients</topic><topic>Retrospective Studies</topic><topic>Ribonucleic acid</topic><topic>RNA</topic><topic>Safety</topic><topic>Side effects</topic><topic>Surgery</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Yuanyuan</creatorcontrib><creatorcontrib>Li, Linghua</creatorcontrib><creatorcontrib>Liu, Jun</creatorcontrib><creatorcontrib>Zhang, Da-Wei</creatorcontrib><creatorcontrib>Zhao, Fang</creatorcontrib><creatorcontrib>Wang, Li</creatorcontrib><creatorcontrib>Mahemure, Aizezi</creatorcontrib><creatorcontrib>Xie, Ronghui</creatorcontrib><creatorcontrib>Lei, Suyun</creatorcontrib><creatorcontrib>Cai, Weiping</creatorcontrib><creatorcontrib>Wang, Xicheng</creatorcontrib><creatorcontrib>Shu, Zhanjun</creatorcontrib><creatorcontrib>Chen, Xiejie</creatorcontrib><creatorcontrib>Wang, Hui</creatorcontrib><creatorcontrib>Wang, Fu-Sheng</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Toxicology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Hepatology international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Yuanyuan</au><au>Li, Linghua</au><au>Liu, Jun</au><au>Zhang, Da-Wei</au><au>Zhao, Fang</au><au>Wang, Li</au><au>Mahemure, Aizezi</au><au>Xie, Ronghui</au><au>Lei, Suyun</au><au>Cai, Weiping</au><au>Wang, Xicheng</au><au>Shu, Zhanjun</au><au>Chen, Xiejie</au><au>Wang, Hui</au><au>Wang, Fu-Sheng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tolerable and curable treatment in HIV/HCV co-infected patients using anti-HCV direct antiviral agents: a real-world observation in China</atitle><jtitle>Hepatology international</jtitle><stitle>Hepatol Int</stitle><addtitle>Hepatol Int</addtitle><date>2018-09-01</date><risdate>2018</risdate><volume>12</volume><issue>5</issue><spage>465</spage><epage>473</epage><pages>465-473</pages><issn>1936-0533</issn><eissn>1936-0541</eissn><abstract>Objective
No brand direct-acting antiviral agents (DAAs) are available for treatment of HIV-1/HCV co-infected patients in China. This study aimed to observe the therapeutic efficacy and safety of generic DAAs for affected Chinese patients.
Design
Real-world setting to elucidate whether DAAs were tolerated and effective in HIV-1/HCV co-infected patients.
Methods
176 HIV-1/HCV co-infected patients received anti-HCV DAA treatment together with ART regimens for HIV infection. Among the 176 patients, 99 patients were treated with SOF + DCV ± RBV, 60 patients were treated with SOF + LDV ± RBV, and 17 patients received SOF + RBV ± Peg-IFN regimens, for 12 or 24 weeks, respectively. The primary endpoint was undetectable HCV RNA 12 weeks after therapy was completed (SVR12). Data pertaining to safety and adverse events were analyzed.
Results
151/176 HIV-1/HCV co-infected patients finished the treatment and 12-week follow-up. SVR12 for the patients treated with regimens of SOF + DCV, SOF + DCV+RBV, SOF + Peg-IFN+RBV, SOF + RBV, SOF + LDV, and SOF + LDV+RBV for 12 or 24 weeks was 100% (75/75), 100% (11/11), 100% (14/14), 100% (2/2), 95.2% (40/42), and 100% (7/7), respectively. HIV-1/HCV co-infected patients with liver cirrhosis achieved well SRV12. Notably, there was no significant difference in adverse effects among patients with different baseline CD4
+
T-cell count in those who received DAA regimens with or without Peg-IFN and RBV.
Conclusion
We showed generic SOF + DCV and SOF + LDV regimens were well tolerated and with high efficiency. Patient’s baseline CD4
+
T-cell count did not exhibit significant difference in adverse effects.</abstract><cop>New Delhi</cop><pub>Springer India</pub><pmid>30203381</pmid><doi>10.1007/s12072-018-9891-9</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1936-0533 |
| ispartof | Hepatology international, 2018-09, Vol.12 (5), p.465-473 |
| issn | 1936-0533 1936-0541 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2102320919 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adult Antiretroviral therapy Antiviral agents Antiviral Agents - therapeutic use Antiviral drugs CD4 antigen China Cirrhosis Coinfection - drug therapy Colorectal Surgery Drug Therapy, Combination Drugs, Generic - therapeutic use Female Follow-Up Studies Hepatitis C, Chronic - drug therapy Hepatology HIV HIV Infections - drug therapy HIV-1 Human immunodeficiency virus Humans Interferon Liver Liver cirrhosis Lymphocytes T Male Medicine Medicine & Public Health Middle Aged Original Article Patients Retrospective Studies Ribonucleic acid RNA Safety Side effects Surgery Treatment Outcome |
| title | Tolerable and curable treatment in HIV/HCV co-infected patients using anti-HCV direct antiviral agents: a real-world observation in China |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T13%3A18%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tolerable%20and%20curable%20treatment%20in%20HIV/HCV%20co-infected%20patients%20using%20anti-HCV%20direct%20antiviral%20agents:%20a%20real-world%20observation%20in%20China&rft.jtitle=Hepatology%20international&rft.au=Li,%20Yuanyuan&rft.date=2018-09-01&rft.volume=12&rft.issue=5&rft.spage=465&rft.epage=473&rft.pages=465-473&rft.issn=1936-0533&rft.eissn=1936-0541&rft_id=info:doi/10.1007/s12072-018-9891-9&rft_dat=%3Cproquest_cross%3E2101675739%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2101675739&rft_id=info:pmid/30203381&rfr_iscdi=true |